Cardiac mechanisms for low aerobic power in anthracycline treated, older, long-term breast cancer survivors

Date

2022

Authors

Beaudry, Rhys I.
Haykowsky, Mark J.
MacNamara, James P.
Tucker, Wesley J.
Rao, Roshni
Haley, Barbara
Sarma, Satyam

Journal Title

Journal ISSN

Volume Title

Publisher

BMC

Abstract

Breast cancer survivors have reduced peak aerobic capacity (VO2peak) which may be related to latent or lingering chemotherapy induced cardiac damage. Nine, older (67 ± 3 years), long-term survivors (9.8 years) of anthracycline based chemotherapy and age- and sex-matched healthy controls were recruited and tested to determine whether: i) VO2peak remains reduced in long-term survivorship; and ii) reductions in VO2peak are due to cardiac dysfunction. VO2peak was significantly reduced in breast cancer survivors relative to healthy controls (15.9 ± 2.0 vs 19.9 ± 3.1 ml/kg/min, p = 0.006), however the heart rate and stroke volume responses to exercise were normal (heart rate reserve; 88 ± 9 vs 85 ± 10 bpm, p = 0.62: stroke volume reserve; 13 ± 6 vs 13 ± 9 ml,p = 0.94). These findings indicate low-normal ventricular size in long-term breast cancer survivors, but normal reserve function.

Description

Keywords

Breast cancer, Anthracycline, Cardiac function, Exercise, Aerobic capacity, VO2peak

Citation

This is the published version of an article that is available at https://doi.org/10.1186/s40959-022-00134-1. Recommended citation: Beaudry, R. I., Haykowsky, M. J., MacNamara, J. P., Tucker, W. J., Rao, R., Haley, B., & Sarma, S. (2022). Cardiac mechanisms for low aerobic power in anthracycline treated, older, long-term breast cancer survivors. Cardio-Oncology, 8(1). This item has been deposited in accordance with publisher copyright and licensing terms and with the author’s permission.